GLP1R and obesity due to melanocortin 4 receptor deficiency: While the advent of GLP-1R agonists have indisputably revolutionized the pharmaceutical intervention of obesity, further improvements in efficacy and tolerability are necessary to maximize the long-term health outcomes of patients.